ArticleDisease models & mechanisms2026
C-C motif receptor 2 is a core profibrotic factor in uremic cardiomyopathy.
Article in Disease models & mechanisms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Uremic cardiomyopathy (UC) represents a leading cause of mortality in patients with chronic kidney disease (CKD), characterized by left ventricular hypertrophy (LVH) and fibrosis. The underlying mechanisms of UC pathogenesis remain incompletely understood. This study developed two methods to simulate human UC - modified nephrectomy (MNx) and adenine-normal combinational diet - and compared these approaches across several rodent strains. Transcriptomic analysis was performed on left ventricular tissues from these models. The analysis revealed global changes in UC, including dysregulated cell cycle processes, enhanced extracellular matrix remodeling and metabolic abnormalities, while also highlighting molecular distinctions between MNx- and adenine-induced UC. Notably, this study identified C-C-motif receptor 2 (CCR-2) as a novel potential antifibrotic target in UC. CCR-2 blockade substantially reversed fibrosis without affecting LVH. The mechanism through which CCR-2 inhibition suppresses cardiac fibrosis development in UC appears to involve the promotion of cardiac residual macrophage expansion. These findings establish a central role for CCR-2 in cardiac fibrosis and suggest CCR-2 inhibition as a promising therapeutic target for UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.